Principal Financial Group Inc Tricida, Inc. Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.14 - $12.49 $1,829 - $163,244	13,070 New	13,070 $1,000
Q3 2021 Nov 09, 2021	SELL	$3.56 - $4.64 $41,292 - $53,819	-11,599 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$3.95 - $5.41 $1,880 - $2,575	476 Added 4.28%	11,599 $50,000
Q1 2021 May 10, 2021	BUY	$4.52 - $7.8 $3,543 - $6,115	784 Added 7.58%	11,123 $59,000
Q4 2020 Feb 08, 2021	BUY	$4.37 - $9.46 $1,057 - $2,289	242 Added 2.4%	10,339 $73,000
Q3 2020 Nov 06, 2020	SELL	$8.56 - $26.93 $4,280 - $13,465	-500 Reduced 4.72%	10,097 $91,000
Q2 2020 Aug 05, 2020	BUY	$21.21 - $31.55 $224,762 - $334,335	10,597 New	10,597 $291,000
Q1 2020 May 12, 2020	SELL	$18.43 - $38.04 $132,880 - $274,268	-7,210 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$29.6 - $43.71 $18,914 - $27,930	639 Added 9.72%	7,210 $272,000
Q3 2019 Nov 13, 2019	BUY	$29.87 - $42.22 $3,046 - $4,306	102 Added 1.58%	6,571 $203,000
Q2 2019 Aug 12, 2019	BUY	$31.16 - $39.46 $201,574 - $255,266	6,469 New	6,469 $255,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.